|1.||Demidova, M A: 3 articles (01/2006 - 01/2005)|
|2.||Belousov, Iu B: 3 articles (01/2006 - 01/2005)|
|3.||Aebischer, N J: 2 articles (11/2012 - 05/2002)|
|4.||Davis, C: 2 articles (11/2012 - 05/2002)|
|5.||Leonova, M V: 2 articles (01/2006 - 01/2006)|
|6.||Tarasov, A V: 2 articles (01/2006 - 01/2006)|
|7.||Hlawaty, Marta: 2 articles (01/2005 - 02/2002)|
|8.||Sayegh, Fady: 2 articles (01/2005 - 02/2002)|
|9.||Asmar, Roland: 2 articles (01/2005 - 02/2002)|
|10.||Pines, Amos: 2 articles (01/2003 - 12/2002)|
|1.||Hypertension (High Blood Pressure)
04/20/2005 - "ACE inhibitor moexipril added to combination therapy of hypertension had similar effect on blood pressure reduction and left ventricle mass as in monotherapy trials. "
09/01/1998 - "This trial was intended to assess the effect of combined sequential HRT for 25 days on acute changes in arterial distensibility after a single oral dose of 15 mg moexipril hydrochloride in postmenopausal women with borderline to mild essential hypertension. "
01/01/2007 - "Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. "
04/20/2005 - "To evaluate the effect of ACE inhibitor moexipril if added to combination therapy in patient with poorly controlled hypertension. "
01/01/2005 - "To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life. "
01/01/2006 - "The study of efficacy of moexipril in chronic heart failure in women is able to broaden indications to the use of this drug."
01/01/2005 - "[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure]."
01/01/2005 - "The purpose of the study was to evaluate hemodynamic and anti-ischemic effects of moexipril in patients with postinfarction left ventricular dysfunction (PL VD) and moderate left ventricular heart failure (NYHA functional class II-III). "
01/01/2005 - "The results of the 4-week moexipril administration demonstrate hemodynamic and anti-ischemic effects of the new ACF inhibitor, its positive influence on transcapillary oxygen exchange and MC in patients with PLVD, associated with NYHA functional class II-III heart failure."
|3.||Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
02/01/2010 - "Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid."
02/01/2010 - "We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). "
|5.||Left Ventricular Dysfunction
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|5.||Ursodeoxycholic Acid (Urso)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)